title: Intraoperative electron beam radiotherapy during radical surgery for locally advanced and recurrent cervical cancer.
abstract: OBJECTIVE
  The goal of this study was to determine the toxicity patterns and clinical usefulness of intraoperative electron beam radiotherapy (IOERT) in patients with unfavorable-outcome cervical cancer.
  
  
  METHODS
  From January 1986 to June 1999, 67 patients (36 recurrent, 31 primary disease) were treated with IOERT. Previously unirradiated patients received preoperative chemoradiation to 45 Gy with cisplatin 20 mg/m(2) and 5-fluorouracil 1000 mg/m(2). IOERT median dose was 12 Gy for primary disease (range: 10-25) and 15 Gy for recurrent disease (range: 10-20).
  
  
  RESULTS
  The 10-year control rate within the area treated with IOERT ("in-field" (IF)) for the entire group was 69.4, with 92.8 and 46.4% 10-year IF control rates for the primary and recurrent patients, respectively. IF control rate correlated with involvement of the parametrial margin (P = 0.001), amount of residual disease (P = 0.001), and pelvic lymph node involvement (P = 0.032). The overall incidence of toxic events that might be attributable to IOERT was 14.9%. Chronic pain was observed in 8 of 67 evaluable patients (11.9%) and motor neuropathy of the lower extremity in one patient (3.2%).
  
  
  CONCLUSIONS
  IOERT is a valuable boosting technique in the management of advanced but resectable cervical cancer. Patients, especially recurrent cases, with positive lymph nodes, parametrial involvement, and/or incomplete resections have poor local control rates despite IOERT at the doses used in this study.
authors.affiliation: Department of Oncology, Clinica Universitaria, Univeridad de Navarra, 31080 Pamplona, Spain. rmartinezm@unav.es
authors.forename: R
authors.initials: R
authors.lastname: Martínez-Monge
authors.forename: M
authors.initials: M
authors.lastname: Jurado
authors.forename: J J
authors.initials: JJ
authors.lastname: Aristu
authors.forename: M
authors.initials: M
authors.lastname: Moreno
authors.forename: M
authors.initials: M
authors.lastname: Cambeiro
authors.forename: A
authors.initials: A
authors.lastname: Pérez-Ochoa
authors.forename: G
authors.initials: G
authors.lastname: López-García
authors.forename: J L
authors.initials: JL
authors.lastname: Alcazar
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D004583:Electrons / Q000627:therapeutic use; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D005500:Follow-Up Studies; D006801:Humans; D007430:Intraoperative Care; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy / Q000532:radiotherapy* / Q000601:surgery*; D011878:Radiotherapy / Q000009:adverse effects / Q000379:methods; D015996:Survival Rate; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy / Q000532:radiotherapy* / Q000601:surgery*
chemical_list: D002945:Cisplatin; D005472:Fluorouracil